Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care-an international Delphi study.

Optimal care Palliative care Supportive care Supportive oncology Toxicity

Journal

EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727

Informations de publication

Date de publication:
Oct 2024
Historique:
received: 12 05 2024
revised: 18 08 2024
accepted: 27 08 2024
medline: 23 9 2024
pubmed: 23 9 2024
entrez: 23 9 2024
Statut: epublish

Résumé

Supportive care to ensure optimal quality of life is an essential component of cancer care and symptom control across the lifespan. Ongoing advances in cancer treatment, increasing toxicity from many novel treatment regimes, and variations in access to care and cancer outcomes across the globe and resource settings present significant challenges for supportive care delivery. To date, no overarching framework has been developed to guide supportive care development worldwide. As an initial step of the Multinational Association of Supportive Care in Cancer (MASCC) Supportive Care 2030 Movement, we developed a targeted, unifying set of ambition statements to envision the future of supportive cancer care. From September 2022 until June 2023, we used a modified Delphi methodology to develop and attain consensus about ambition statements related to supportive cancer care. Leaders of MASCC Study Groups were invited to participate in an Expert Panel for the first two Delphi rounds (and a preliminary round to suggest potential ambition statements). Patient Advocates then examined and provided input regarding the ambition statements. Twenty-seven Expert Panelists and 11 Patient Advocates participated. Consensus was attained on 13 ambition statements, with two sub-statements. The ambition statements addressed global standards for guideline development and implementation, coordinated and individualized care, dedicated supportive oncology services, self-management, needs for screening and actions, patient education, behavioral support, financial impact minimization, comprehensive survivorship care, and timely palliative care, reflecting collaboration, coordination and team-based approach across all levels. This study is the first to develop shared ambitions for the future of supportive cancer care on a global level. These ambition statements can facilitate a coordinated, resource-stratified, and person-centered approach and inform research, education, clinical services, and policy efforts. This project received funding support from Prof Raymond Chan's NHMRC Investigator Grant (APP1194051).

Sections du résumé

Background UNASSIGNED
Supportive care to ensure optimal quality of life is an essential component of cancer care and symptom control across the lifespan. Ongoing advances in cancer treatment, increasing toxicity from many novel treatment regimes, and variations in access to care and cancer outcomes across the globe and resource settings present significant challenges for supportive care delivery. To date, no overarching framework has been developed to guide supportive care development worldwide. As an initial step of the Multinational Association of Supportive Care in Cancer (MASCC) Supportive Care 2030 Movement, we developed a targeted, unifying set of ambition statements to envision the future of supportive cancer care.
Methods UNASSIGNED
From September 2022 until June 2023, we used a modified Delphi methodology to develop and attain consensus about ambition statements related to supportive cancer care. Leaders of MASCC Study Groups were invited to participate in an Expert Panel for the first two Delphi rounds (and a preliminary round to suggest potential ambition statements). Patient Advocates then examined and provided input regarding the ambition statements.
Findings UNASSIGNED
Twenty-seven Expert Panelists and 11 Patient Advocates participated. Consensus was attained on 13 ambition statements, with two sub-statements. The ambition statements addressed global standards for guideline development and implementation, coordinated and individualized care, dedicated supportive oncology services, self-management, needs for screening and actions, patient education, behavioral support, financial impact minimization, comprehensive survivorship care, and timely palliative care, reflecting collaboration, coordination and team-based approach across all levels.
Interpretation UNASSIGNED
This study is the first to develop shared ambitions for the future of supportive cancer care on a global level. These ambition statements can facilitate a coordinated, resource-stratified, and person-centered approach and inform research, education, clinical services, and policy efforts.
Funding UNASSIGNED
This project received funding support from Prof Raymond Chan's NHMRC Investigator Grant (APP1194051).

Identifiants

DOI: 10.1016/j.eclinm.2024.102825 PMID: 39309723 PMC: PMC11415959
pubmed: 39309723
doi: 10.1016/j.eclinm.2024.102825
pii: S2589-5370(24)00404-8
pmc: PMC11415959
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102825

Informations de copyright

Crown Copyright © 2024 Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

All authors declare their leadership roles within the Multinational Association for Supportive Care in Cancer. The individual authors also reported their respective conflicts of interest, however are not judged to be directly relevant to the conduct of this study. FA reported reimbursement from VieCure for travel-related expenses to attend ASCO 2024 and MASCC 2024; US Patent No. 11, 798,689 B2: AI decision-support platform to generate patient-specific health plans based on unique patient circumstances; Clinical Advisory Committee Chair—VieCure; Stock—VieCure Oncology Decision Support Platform. IO reported receiving reimbursement from MASCC to travel to 2022 and 2023 MASCC Annual Scientific Meetings; and Chair of SAX Institute Board. CT reported Leadership or fiduciary roles: Executive Director, Global Focus on Cancer; Advisory Board, Asia Pacific Oncology Alliance; Steering Committee, WHO Symposium on Meaningful Engagement; Editorial Board, Cancer Survivorship Research & Care Journal. PB reported receiving consulting fees from Angelini, Nestle, Nutricia and Molteni; and participation on Angelini Advisory Board/Data Safety Monitoring Board. TN reported receiving research funding from Otsuka Pharmaceutical CO, Ltd, and Kracie Ltd; and lecture fee for ONO Pharmaceutical CO Ltd. ADO reported Pfizer stock ownership. HW reported she is the recipient of a Hospital Research Foundation Research Fellowship. FS reported payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from BMS, Sanofi, Roche, MSD, Prostrakan, Leo pharma, Janssen, Pfizer, Amgen, Pierre Fabre Oncologie, Pharmanovia, Vifor Pharma, GSK, Viatris, Helsinn, Gilead, and Daichy Sankyo. PA reported receiving grant (250.000 euros) from Cariplo Foundation; consulting fees from GHD Healthcare, Oncosultions, LLC, and Techspert. IO LTD.

Auteurs

Raymond Javan Chan (RJ)

Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Flinders Drive, Bedford Park, South Australia, Australia.

Reegan Knowles (R)

Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Flinders Drive, Bedford Park, South Australia, Australia.

Fredrick D Ashbury (FD)

Department of Oncology, University of Calgary, Alberta, Canada.

Joanne Bowen (J)

School of Biomedicine, Faculty of Health and Medical Sciences, University of Adelaide, 230 North Terrace, Adelaide, South Australia, Australia.

Alexandre Chan (A)

Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, University of California, 802 W Peltason Dr, Irvine, CA, United States.

Melissa Chin (M)

Multinational Association of Supportive Care in Cancer, 16 Industrial Parkway South Unit 412, Aurora, ON L4G 0R1, Canada.

Ian Olver (I)

School of Psychology, Faculty of Health and Medical Sciences, University of Adelaide, 230 North Terrace, Adelaide, South Australia, Australia.

Carolyn Taylor (C)

Global Focus on Cancer, 26 Hemlock Rd Suite 101, South Salem, NY 10590, United States.

Stacey Tinianov (S)

Advocates for Collaborative Education, Santa Cruz, CA, United States.

Paola Alberti (P)

School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.

Paolo Bossi (P)

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan 20072, Italy.
IRCCS Humanitas Research Hospital, via Manzoni 56, Rozzano, Milan 20089, Italy.

Norman Brito-Dellan (N)

The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, United States.

Tim Cooksley (T)

The Christie, Wilmslow Rd, Manchester, United Kingdom.

Gregory Brian Crawford (GB)

School of Psychology, Faculty of Health and Medical Sciences, University of Adelaide, 230 North Terrace, Adelaide, South Australia, Australia.
Northern Adelaide Local Health Network, South Australia, Australia.

Niharika Dixit (N)

Division of Hematology/Oncology, University of California, San Francisco, CA, United States.
Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA, United States.

Margaret I Fitch (MI)

Bloomberg Faculty of Nursing, University of Toronto, 155 College Str, Suite 130, Toronto, Ontario, Canada.

Jason L Freedman (JL)

Division of Oncology, Children's Hospital of Philadelphia, 3400 Civic Center Blvd, Philadelphia, PA, United States.
Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, United States.

Pamela K Ginex (PK)

State University of New York, Nicolls Rd, Stony Brook, NY, United States.

Nicolas H Hart (NH)

Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Flinders Drive, Bedford Park, South Australia, Australia.
Human Performance Research Centre, INSIGHT Research Institute, Faculty of Health, University of Technology Sydney (UTS), 235 Jones Str, Ultimo, Sydney, New South Wales, Australia.

Daniel L Hertz (DL)

Department of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church Str, Ann Arbor, MI, United States.

Michael Jefford (M)

Department of Health Services Research, Peter MacCallum Cancer Centre, 305 Grattan Str, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, 305 Grattan Str, Melbourne, Victoria, Australia.

Bogda Koczwara (B)

Flinders Medical Centre, Flinders Drive, Bedford Park, South Australia, Australia.
Flinders University, Flinders Health and Medical Research Institute, Flinders Drive, Bedford Park, South Australia, Australia.

Tateaki Naito (T)

Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Japan.

Andrea Dahlman Orsey (AD)

Center for Cancer and Blood Disorders, Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT 06106, United States.
Department of Pediatrics, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, United States.

Christina H Ruhlmann (CH)

Department of Oncology, Odense University Hospital, Denmark - Department of Clinical Research, University of Southern Denmark, Denmark.

Nikolaos Tsoukalas (N)

Oncology Department, 401 General Military Hospital of Athens, Greece.

Corina van den Hurk (C)

R&D Department, Netherlands Comprehensive Cancer Organization (IKNL), Rijnkade 5, Utrecht 3511 LC, the Netherlands.

Ysabella Van Sebille (Y)

University of South Australia, Level 4, Catherine Helen Spence Building, City West, Adelaide, South Australia, Australia.

Hannah Rose Wardill (HR)

School of Biomedicine, Faculty of Health and Medical Sciences, University of Adelaide, 230 North Terrace, Adelaide, South Australia, Australia.
The Supportive Oncology Research Group, Precision Cancer Medicine Theme, The South Australian Health and Medical Research Institute, North Terrace, Adelaide, South Australia, Australia.

Florian Scotte (F)

Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif CEDEX, Paris, France.

Maryam Lustberg (M)

Smilow Cancer Hospital at Yale, 35 Park Street, Fl 1st, Suite A, New Haven, CT 06511, United States.

Classifications MeSH